LAFAYETTE, La., April 22, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, today announced that it will host its First Quarter 2025 Earnings Conference Call on Thursday, May 8, 2025, at 11:00 a.m. EDT.
Interested parties may participate in the call by dialing:
(866) 682-6100 (US Toll-Free)
+1 (862) 298-0702 (International)
Live Audio Webcast - Click Here
Following the live call, a replay will be available in the Investor Relations section of the Company’s website at www.viemed.com.
ABOUT VIEMED HEALTHCARE, INC.
Viemed is an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, including non-invasive ventilators (NIV), sleep therapy, staffing, and other complementary products and services. Viemed focuses on efficient and effective in-home treatment with clinical practitioners providing therapy, education and counseling to patients in their homes using high-touch and high-tech services. Visit our website at www.viemed.com.
For further information, please contact:
Tripp Sullivan
SCR Partners, LLC
615-942-7077
This email address is being protected from spambots. You need JavaScript enabled to view it.
Todd Zehnder
Chief Operating Officer
Viemed Healthcare, Inc.
337-504-3802
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$6.85 |
Daily Change: | -0.04 -0.58 |
Daily Volume: | 238,440 |
Market Cap: | US$265.710M |
October 14, 2025 March 10, 2025 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load